Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Historically, the North American Brain Tumor Consortium used 6-month progression-free survival (PFS6) as the primary outcome for recurrent glioma phase II clinical trials. In some trials, a subset of patients received the trial treatment before surgery to assess tumor uptake and biological activity....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Clarke†, Jennifer L., Ennis†, Michele M., Yung, W. K. Alfred, Chang, Susan M., Wen, Patrick Y., Cloughesy, Timothy F., DeAngelis, Lisa M., Robins, H. Ian, Lieberman, Frank S., Fine, Howard A., Abrey, Lauren, Gilbert, Mark R., Mehta, Minesh, Kuhn, John G., Aldape, Kenneth D., Lamborn, Kathleen R., Prados, Michael D.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2011
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3177665/
https://ncbi.nlm.nih.gov/pubmed/21813511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars